Target-specific oral anticoagulants (TSOACs), including apixaban, dabigatran, and rivaroxaban, are recommended over warfarin.1,2 Atrial fibrillation quality improvement initiatives have increased adherence to guideline-recommended anticoagulation for stroke prevention.3 Although TSOACs have better safety profiles than warfarin, hemorrhage remains a common adverse event.4 Even moderate decreases in estimated glomerular filtration rate (eGFR) increase hemorrhage risk related to warfarin, a drug with predominately nonrenal clearance.